ES2116801T3 - Empleo de derivados de adamantano para el tratamiento de tinnitus. - Google Patents

Empleo de derivados de adamantano para el tratamiento de tinnitus.

Info

Publication number
ES2116801T3
ES2116801T3 ES96112325T ES96112325T ES2116801T3 ES 2116801 T3 ES2116801 T3 ES 2116801T3 ES 96112325 T ES96112325 T ES 96112325T ES 96112325 T ES96112325 T ES 96112325T ES 2116801 T3 ES2116801 T3 ES 2116801T3
Authority
ES
Spain
Prior art keywords
tinnitus
treatment
adamantane derivatives
alkyl
adamantane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96112325T
Other languages
English (en)
Inventor
Hans Peter Prof Dr Med Zenner
J Peter Prof Dr Ruppersberg
Andreas Dr Busch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TINNITUS FORSCHUNGS und ENTWIC
Original Assignee
TINNITUS FORSCHUNGS und ENTWIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TINNITUS FORSCHUNGS und ENTWIC filed Critical TINNITUS FORSCHUNGS und ENTWIC
Application granted granted Critical
Publication of ES2116801T3 publication Critical patent/ES2116801T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UTILIZACION DE DERIVADOS DEL ADAMANTANO DE FORMULA EN DONDE R{SUB,1} Y R{SUB,2} SON - IGUALES O DIFERENTES Y PUEDEN SER HIDROGENO O GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, O - FORMAR JUNTO CON EL ATOMO DE N UN HETEROCICLO CON 5 O 6 ATOMOS, R{SUB,3} Y R{SUB,4} SON, IGUALES O DIFERENTES, HIDROGENO, GRUPOS ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C, GRUPOS CICLOALQUILO CON 5 O 6 ATOMOS DE C, O EL GRUPO FENILO, Y EN DONDE R{SUB,5} PUEDE SER HIDROGENO O UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 6 ATOMOS DE C; PARA EL TRATAMIENTO DE ENFERMEDADES DEL OIDO INTERNO.
ES96112325T 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus. Expired - Lifetime ES2116801T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs

Publications (1)

Publication Number Publication Date
ES2116801T3 true ES2116801T3 (es) 1998-07-16

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96112325T Expired - Lifetime ES2116801T3 (es) 1995-08-02 1996-07-31 Empleo de derivados de adamantano para el tratamiento de tinnitus.

Country Status (14)

Country Link
US (1) US6066652A (es)
EP (2) EP0834310A1 (es)
JP (1) JP3568039B2 (es)
KR (1) KR100393296B1 (es)
CN (1) CN1142775C (es)
AT (1) ATE163545T1 (es)
AU (1) AU719018B2 (es)
BR (1) BR9609950A (es)
DE (3) DE19528388A1 (es)
DK (1) DK0759295T3 (es)
ES (1) ES2116801T3 (es)
IL (1) IL123142A (es)
PL (1) PL324795A1 (es)
WO (1) WO1997004762A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US7132406B2 (en) 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ES2292611T3 (es) * 2000-08-08 2008-03-16 Evergreen Packaging International B.V. Procedimiento para la activacion de componentes secuestradores de oxigeno durante un proceso de llenado de cajas de carton con tapa de pico.
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1325743A4 (en) 2000-10-13 2004-12-15 Chugai Pharmaceutical Co Ltd COMPOSITIONS TO IMPROVE FAT METABOLISM
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP2006502158A (ja) * 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
JP2008537684A (ja) * 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP2932971A1 (en) * 2005-03-04 2015-10-21 Otonomy, Inc. Ketamine formulations
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US20080152694A1 (en) * 2006-07-20 2008-06-26 Neurosystec Corporation Devices, Systems and Methods for Ophthalmic Drug Delivery
WO2008016602A2 (en) * 2006-07-31 2008-02-07 Neurosystec Corporation Free base gacyclidine nanoparticles
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
CN101801366A (zh) * 2007-09-12 2010-08-11 莫茨药物股份两合公司 用于neramexane的逐步增量包装和其在治疗内耳病中的用途
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
PL324795A1 (en) 1998-06-22
DK0759295T3 (da) 1999-01-25
EP0834310A1 (de) 1998-04-08
AU719018B2 (en) 2000-05-04
DE19680619D2 (de) 1998-10-29
WO1997004762A1 (de) 1997-02-13
CN1194581A (zh) 1998-09-30
KR100393296B1 (ko) 2003-11-17
ATE163545T1 (de) 1998-03-15
KR19990036073A (ko) 1999-05-25
CN1142775C (zh) 2004-03-24
JP2000515486A (ja) 2000-11-21
DE59600105D1 (de) 1998-04-09
MX9800925A (es) 1998-10-31
IL123142A0 (en) 1998-09-24
IL123142A (en) 2001-10-31
EP0759295A1 (de) 1997-02-26
BR9609950A (pt) 1999-06-29
EP0759295B1 (de) 1998-03-04
DE19528388A1 (de) 1997-02-06
US6066652A (en) 2000-05-23
JP3568039B2 (ja) 2004-09-22
AU6788296A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
DK0759295T3 (da) Anvendelse af adamantan-derivater til behandling af tinnitus
NO960380L (no) Middel til behandling av neurosykdommer
ATE153240T1 (de) Behandlung peri-menopausaler syndrome
ATE384524T1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
ES2106573T3 (es) Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma.
NO305174B1 (no) Heterocykliske forbindelser
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
NO943521D0 (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
CO4410336A1 (es) Derivados de quinoxalina utiles en terapia
DE69603667D1 (de) Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
NO971743L (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
PT1068184E (pt) Derivados n-ariloxietilamina para o tratamento de depressao
NO942668L (no) Alkylderivater av trazodon med CNS-aktivitet
ES2053612T3 (es) Agentes para la proteccion contra enfermedades de las plantas.
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
EP0785193A4 (en) ARYLTHIADIAZOLE DERIVATIVE AND ANTIVIRAL AGENT CONTAINING THE SAME
MX9306879A (es) Derivados de piperazina y composiciones farmaceuticas que los contienen,para el tratamiento de enfermedades del conocimiento.
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler
CO4290357A1 (es) Derivados de la cefalosporina, preparaciones farmaceuticas que las contienen y procedimiento para su preparacion y em- pleo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759295

Country of ref document: ES